Hip DAA Closure Techniques
Launched by ROTHMAN INSTITUTE ORTHOPAEDICS · Aug 17, 2023
Trial Information
Current as of June 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
The use of the direct anterior approach (DAA) for primary total hip arthroplasty (THA) has been increasingly popular but there has been a reported increased risk of wound complications compared with a posterior approach. Wound complications can lead to increased length of stay, reoperation procedures (i.e., irrigation and debridement), patient dissatisfaction, extra visits, readmissions, increased risk of periprosthetic joint infection and overall increased costs.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients older than 18 years old that will undergo THA via DAA
- Exclusion Criteria:
- • Previous hip arthroplasty surgeries or scars
- • THA secondary to oncologic or traumatic etiologies
- • BMI ≥ 40
- • uncontrolled diabetes (measured by a Hgb A1c above 8)
- • reported allergy to skin adhesive
About Rothman Institute Orthopaedics
Rothman Institute Orthopaedics is a leading healthcare organization specializing in orthopedic care and research. With a commitment to advancing the field of orthopedics, Rothman Institute conducts innovative clinical trials aimed at improving patient outcomes and enhancing treatment methodologies. Renowned for its team of highly skilled orthopedic surgeons and researchers, the institute integrates cutting-edge technology and evidence-based practices to deliver exceptional care. Through its rigorous research initiatives, Rothman Institute is dedicated to fostering advancements in orthopedic medicine and contributing to the overall improvement of musculoskeletal health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Philadelphia, Pennsylvania, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported